Rewriting Life

The Right Decision

Before consenting to a medical procedure, a patient usually asks a key set of questions. What is the surgeon’s success rate in performing the procedure? What are the risks involved? What are the typical post-op results?

Each of these questions weighed heavily on my mind the morning of October 4, 2010, the day I confronted the idea of becoming the first human candidate for embryonic-stem-cell therapy. Yet after reading over the 31 pages of a first-ever clinical protocol and investigator’s brochure, I knew these questions could never be answered.

As I stared down at the pages, it was hard to grasp that just 10 days after being involved in a car accident—one that left me paralyzed from the chest down—I was now being faced with the biggest decision of my life.

I was a student at the University of South Alabama Nursing School, so I understood there were significant risks to being the first patient enrolled in any clinical trial. But nothing could prepare me for being the first person with a spinal-cord injury to be injected with more than two million cells grown in a laboratory from human embryonic stem cells. I kept thinking about a lecture on the promise of regenerative medicine I had attended only two weeks before the accident. It put in perspective what my participation could mean to millions of other disabled people.

After discussing the pros and cons of the procedure with my mother and maternal grandfather, I realized that I had a great responsibility to fulfill. I’d be the one to help doctors and researchers learn how these cells actually work in humans. I’d be able to encourage continued research in this controversial field from the perspective of someone who had been through the type of injury the researchers hope to treat.

Less than 30 minutes after being informed of the risks involved in the trial, I signed my name to the consent forms and initialed each page. Even under the pressure of the situation, I knew I was making the right decision. There were no false expectations about the infallibility of science, but I was doing this with the faith that I’d walk again one day. My faith carried me through it all.

Nearly eight months after being injected, I remain confident in my decision. However, I do admit that with each passing day, the fear of tumors developing at the injection site troubles me more. I find peace in the fact that even if this were to occur, I’d be helping researchers learn something about the procedure and what to avoid next time. Even if I became sick, I would still be contributing to the health of someone else, somewhere down the line.

Read the Feature Article: Stem-Cell Gamble

T. J. Atchison is collaborating with Tory Minus, the editor of Alabama Living, on a book about his experience.

The latest Insider Conversation is live! Listen to the story behind the story.

Subscribe today
Already a Premium subscriber? Log in.

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe and become an Insider.
  • Insider Premium {! insider.prices.premium !}*

    {! insider.display.menuOptionsLabel !}

    Our award winning magazine, unlimited access to our story archive, special discounts to MIT Technology Review Events, and exclusive content.

    See details+

    What's Included

    Bimonthly magazine delivery and unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

    First Look: exclusive early access to important stories, before they’re available to anyone else

    Insider Conversations: listen in on in-depth calls between our editors and today’s thought leaders

  • Insider Plus {! insider.prices.plus !}* Best Value

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus ad-free web experience, select discounts to partner offerings and MIT Technology Review events

    See details+

    What's Included

    Bimonthly magazine delivery and unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning magazine and daily delivery of The Download, our newsletter of what’s important in technology and innovation.

    See details+

    What's Included

    Bimonthly magazine delivery and unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.